APA (7th ed.) Citation

Démaris, A., Widigson, E. S. K., Ilvemark, J. F. K. F., Steenholdt, C., Seidelin, J. B., Huisinga, W., . . . Kloft, C. (2022). Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review. Pharmaceutics, 14(10), N.PAG. https://doi.org/10.3390/pharmaceutics14102095

Chicago Style (17th ed.) Citation

Démaris, Alix, Ella S. K. Widigson, Johan F. K. F. Ilvemark, Casper Steenholdt, Jakob B. Seidelin, Wilhelm Huisinga, Robin Michelet, Linda B. S. Aulin, and Charlotte Kloft. "Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review." Pharmaceutics 14, no. 10 (2022): N.PAG. https://doi.org/10.3390/pharmaceutics14102095.

MLA (9th ed.) Citation

Démaris, Alix, et al. "Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review." Pharmaceutics, vol. 14, no. 10, 2022, p. N.PAG, https://doi.org/10.3390/pharmaceutics14102095.